GLP-2 TZ (Tirzepatide)

Description

GLP-2 TZ (Tirzepatide) is a premium research peptide often classified as a “Dual Agonist.” It represents a significant advancement over single-receptor peptides by targeting both the GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-like Peptide-1) receptors.

What is GLP-2 TZ (Tirzepatide)?

This peptide is a synthetic combination that mimics the action of two naturally occurring incretin hormones.

1. GIP Receptor Agonism: Unlike Semaglutide (which only hits GLP-1), Tirzepatide activates GIP receptors. Research suggests GIP works synergistically to improve lipid metabolism and insulin sensitivity.

2. GLP-1 Receptor Agonism: Continues to support satiety signaling and glucose regulation.

Research Applications: The “Dual” Effect

Researchers utilize GLP-2 TZ to investigate the “Twincretin” effect—where hitting both receptors yields results superior to GLP-1 alone.

• Metabolic Synergy: Studies in animal models show that adding GIP stimulation allows for greater metabolic control without significantly increasing adverse events common to GLP-1 monotherapy.

• Adipose Tissue Targeting: Research indicates GIP receptors are abundant in adipose (fat) tissue, suggesting this peptide may have a direct mechanism for altering fat utilization that single agonists lack.

  ---

Published Research & Clinical Data

At Guardian Labs, we base our product standards on peer-reviewed science. Below are the pivotal studies regarding Tirzepatide.

• Study 1: The SURMOUNT-1 Trial (Obesity)

  • Title: Tirzepatide Once Weekly for the Treatment of Obesity

  • Summary: This landmark Phase 3 trial demonstrated that Tirzepatide achieved substantial reductions in body weight (up to 20.9%) in non-diabetic subjects, significantly outperforming placebo.

  • Read the full study on NEJM

• Study 2: The SURPASS-2 Trial (vs. Semaglutide)

  • Title: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

  • Summary: A head-to-head study comparing Tirzepatide directly against Semaglutide (Ozempic/Wegovy). The results showed Tirzepatide was superior in both A1C reduction and body weight reduction.

  • Read the full study on NEJM

    ---

Storage and Handling

• Format: Sterile Lyophilized Powder.

• Storage: Store at -20°C (Freezer).

• Reconstitution: Reconstitute with bacteriostatic water.

Why Choose Guardian Labs?

Our GLP-2 TZ is rigorously tested to ensure the dual-agonist peptide structure is intact and pure. We provide the reliability required for high-level metabolic research. For bulk research inquiries, please Contact Us.

For Research Use Only: This product (GLP-2 TZ / Tirzepatide) is intended strictly for laboratory and research purposes. It is not intended for human consumption, injection, or use as a drug, food, or cosmetic.

Handling and Usage:

• This product should only be handled by qualified professionals or researchers.
• The material is supplied in a lyophilized (freeze-dried) state and requires reconstitution with bacteriostatic water or a sterile solvent.
• By purchasing this product, the buyer acknowledges that they understand the potential hazards associated with the handling of research chemicals.

Legal Compliance: Guardian Labs does not endorse the use of this product for performance enhancement or medical treatment. All buyers must be at least 18 years of age.